U.S. reimbursement prospects for bone densitometry are improving,with a growing list of state Medicare and Medicaid payors supportingthe procedure, according to David Ellenbogen, president of densitometervendor Hologic of Waltham MA. But the worldwide
U.S. reimbursement prospects for bone densitometry are improving,with a growing list of state Medicare and Medicaid payors supportingthe procedure, according to David Ellenbogen, president of densitometervendor Hologic of Waltham MA. But the worldwide bone densitometrymarket will remain sluggish until several osteoporosis therapiesunder development reach market.
While Hologic breaks even on its densitometry business, thefirm is searching for alliances or acquisitions to expand in relatedtechnological areas until its core market hits its stride. Thevendor hopes to build on its imaging expertise and distributionpresence, particularly in areas related to women's health, Ellenbogentold SCAN.
Medical investment broker WDI Capital Markets of Hilton Head,SC, has been engaged by Hologic to search for diversificationprospects, he said.
Hologic is interested in company acquisitions, product acquisitionsor strategic alliances, he said. The publicly held company hasabout $10 million in cash and the prospect of further stock offeringsto fund acquisitions.
"Preventive medicine--and women's health as a subset ofthat--is receiving more attention these days. We think there areopportunities in this area for products that are cost-effective,"Ellenbogen said.
Hologic attempted to develop an equalization radiography productin cooperation with Konica, but the two firms dropped the ideaafter Kodak introduced its Insight film line. The differentialscreen-film process accomplishes much of what equalization radiographydoes without requiring an additional capital expenditure, he said.
Hologic successfully spun off a private company, Vivid Technologies,to apply densitometry technology to airport baggage scanning.Vivid, which is backed by Hologic's original venture capital supporters,provides royalties to the firm for licensed technology, he said.
BRIEFLY NOTED:
The Quest is unique among PET scanners in its use of sodiumiodide as a scintillation material. Other systems require costlierbismuth germanate elements. Consequently, the $1.7 million Questfits a low-cost price niche for GE, which introduced the $2.5million Advance in 1992.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.